Amarin Corp Plcuk (AMRN) Depreciation and Depletion (2015 - 2016)
Amarin Corp Plcuk (AMRN) reported Depreciation and Depletion of -$14000.0 for Q4 2016, down 118.67% year-over-year from $75000.0 in Q1 2016, and down 140.0% quarter-over-quarter from $35000.0 in Q3 2016.
Amarin Corp Plcuk (AMRN) Depreciation and Depletion (2015 - 2016) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 2 years of Depreciation and Depletion data on file, last reported at -$14000.0 in Q4 2016.
- Depreciation and Depletion for Q4 2016 came in at -$14000.0, down 118.67% year-over-year; the trailing twelve-month figure through Dec 2016 was $136000.0 (changed N/A YoY), and the FY2025 annual result was $100000.0, changed 0.0% from the prior year.
- Depreciation and Depletion slipped to -$14000.0 in Q4 2016 per AMRN's latest filing, from $35000.0 in the prior quarter.
- Over five years, Depreciation and Depletion peaked at $75000.0 in Q4 2015 and troughed at -$14000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 188.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 139.00 Mn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -14,000.00 |
| Dec 31, 2016 | -14,000.00 |
| Sep 30, 2016 | 35,000.00 |
| Sep 30, 2016 | 35,000.00 |
| Dec 31, 2015 | 75,000.00 |
| Dec 31, 2015 | 75,000.00 |
| Sep 30, 2015 | 40,000.00 |
| Sep 30, 2015 | 40,000.00 |